← Oncology Approval Tracker

FDA DECISION ·

Danyelza + GM-CSF

naxitamab-gqgk + granulocyte-macrophage colony-stimulating factor · Y-mAbs Therapeutics

Accelerated approvalNew therapyNeuroblastoma
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Adults and children ages one year and older with relapsed or refractory high-risk neuroblastoma in bone or bone marrow who had a partial response, minor response or stable disease with prior therapy.

LAMPGEN ANALYSIS

Why it matters

Added an anti-GD2 antibody combination for a narrowly defined high-risk neuroblastoma population under accelerated approval.

What research teams should watch

Capture the prior response category and plan infusion pain management and blood-pressure monitoring.

PRIMARY RECORDS

Sources